Browse Penn-owned technologies available for licensing.
This invention describes construction and initial functional testing of engineered chimeric antigen receptors transduced into human T-cells (CAR-T cells) for selective killing of melanocytes and melanoma cells.
Invasive melanoma is the most lethal and costly skin cancer with over 75,000 new cases and 10,000 deaths per year in the U.S with more than one life claimed every hour. Over the past few years, immunotherapy that target common genetic mutations has dramatically changed the landscape of melanoma treatment but some patients with advanced metastatic melanoma still have a significant risk of mortality. New therapeutic approaches are needed.
Dr. Ridky proposes a CAR-T cell based technology to selective killing of melanocytes. These CAR’s do not target uveal melanocytes. Killing of melanoma cells and melanocytes, with little to no killing of human fibroblasts using these engineered CAR T-cells was shown in vitro as well as in vivo in NSG mice. But melanocytes are dispensable.
Stage of Development:
Killing of melanoma cells and melanocytes in vitro and in in vivo in NSG mice.
Docket # 17-8000